EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH

View source ↗

Summary

Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel Hexal (clopidogrel)

Snippet

Status: Withdrawn. Therapeutic area: Peripheral Vascular Diseases;Acute Coronary Syndrome;Myocardial Infarction;Stroke. MAH: Acino Pharma GmbH. Decision date: 09/02/2012